Scinai Immunotherapeutics Ltd.(SCNI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.3M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SCNI Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Scinai Immunotherapeutics Ltd. (SCNI), a Healthcare sector company. SCNI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.3m in revenue. Based on the latest XBRL financial filings (FY 2025), Scinai Immunotherapeutics Ltd. reports quarterly revenue of $1.3M, net income of $-8.3M, free cash flow of $-6.1M. Top institutional holders of SCNI by reported 13-F value include XTX Topco Ltd, RHUMBLINE ADVISERS, UBS Group AG, based on the most recent SEC filings. SCNI trades on the Nasdaq exchange and files with the SEC under CIK 1611747. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SCNI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Scinai Immunotherapeutics Ltd. directly from SEC EDGAR.
Revenue
FY 2025
$1.3M
Net Income
FY 2025
$-8.3M
Free Cash Flow
FY 2025
$-6.1M
AI Insight: SCNI Financial Trends
Scinai turned equity positive from Q4 2024 onward after years of negative equity, but sparse financial data limits trend analysis.
• Equity improved dramatically from -$7M in Q2 2024 to $10M in Q4 2024, remaining at $8M through Q4 2025.
⚠ Equity declined slightly from $10M in Q4 2024 to $8M by Q4 2025, suggesting potential cash burn.
⚠ No revenue, operating income, or cash flow data available for recent quarters limits visibility into operations.
AI Insight: SCNI Ratio Trends
Data is too sparse to identify meaningful financial trends for Scinai Immunotherapeutics.
• ROA deteriorated from -60.4% in Q1 2023 to -75.6% in Q2 2023.
⚠ Most financial ratios unavailable across periods, limiting visibility into operational performance.
Get alerted when SCNI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Scinai Immunotherapeutics Ltd. including:
Top Institutional Holders of SCNI
XTX Topco Ltd
$13.3K24,041 shRHUMBLINE ADVISERS
$1.0K1,878 shUBS Group AG
$524.00919 shMORGAN STANLEY
$33.0058 sh
| Fund | Value | Shares |
|---|---|---|
| XTX Topco Ltd | $13.3K | 24,041 |
| RHUMBLINE ADVISERS | $1.0K | 1,878 |
| UBS Group AG | $524.00 | 919 |
| MORGAN STANLEY | $33.00 | 58 |
More Healthcare Companies
View all Healthcare →Put SCNI on your watchlist
Track score changes the day Scinai Immunotherapeutics Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SCNI a good stock to buy?
13F Pro's AI-powered analysis of Scinai Immunotherapeutics Ltd. (SCNI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SCNI are available on the SCNI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SCNI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SCNI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Scinai Immunotherapeutics Ltd.'s investment landscape.